Dose Insider / Analyses / Wegovy dosing schedule

Wegovy Dosing ScheduleEvery Step of the Injection, the New 7.2 mg Dose and the Tablets, With Your Dates

Updated November 20, 2026 · 16 min read · FDA label revised June 2026, STEP trials

Wegovy injections start at 0.25 mg once a week and rise every 4 weeks: 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg from week 17. The maintenance dose is 2.4 mg, or 1.7 mg if that suits you better. Since March 2026 adults who have tolerated 2.4 mg for at least 4 weeks can go up to 7.2 mg, the new maximum.

16 weekson four smaller doses before 2.4 mg starts in week 17
When each Wegovy injection dose startsFDA label, the standard schedule0.25 mgweek 10.5 mgweek 51 mgweek 91.7 mgweek 132.4 mgweek 17When each Wegovy injectiondose startsFDA label, the standard schedule0.25 mgweek 10.5 mgweek 51 mgweek 91.7 mgweek 132.4 mgweek 17

Each dose lasts 4 weeks before the next step; 2.4 mg is reached in week 17.

On this page

That is the schedule in the current FDA label, revised in June 2026.1 The same label now covers a second form, a daily tablet, with its own steps: 1.5 mg, 4 mg and 9 mg for 30 days each, then 25 mg.

The calculator puts dates on every step for either form. Below it the page goes through what each maintenance dose delivered in the trials, what changed with the 7.2 mg dose, how the tablets differ, and what the label says when a step is too much or a dose is missed.

What is the Wegovy dosing schedule, with dates?

Enter the date of your first dose, choose the injection or the tablets, and pick the maintenance dose you are heading for. If a step has to be held longer, add the delay and the later dates move with it.

Your Wegovy scheduleFDA label, section 2
Form
Maintenance dose you are heading for
Extra weeks on the last step before it
Maintenance dose starts—
Time to get there—

    The app keeps this schedule for you: it logs each dose and shows the date of the next step.

    Open the app

    A calendar built from the label's schedule. Your prescriber decides when and whether the dose changes.

    The Wegovy schedule is stricter than most people expect in one way and looser in another. The four steps before the maintenance dose are fixed at 4 weeks each in the label's table. But the label also expects that some people will need longer: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks."1 A delayed step is part of the schedule as written.

    What are the Wegovy doses, step by step?

    The injection comes in six strengths. Four are steps on the way up, and the last three can each be where you stay.

    Cheat sheetWegovy injection: the label schedule
    FDA label, June 2026
    DoseWeeksFirst dose on dayWhat it is
    0.25 mg1 to 41Starting dose
    0.5 mg5 to 829Step
    1 mg9 to 1257Step
    1.7 mg13 to 1685Step, and a maintenance dose
    2.4 mg17 onward113The recommended maintenance dose
    7.2 mg21 onward at the earliest141Maximum dose, adults, after 4 weeks or more on 2.4 mg
    A step can be delayed by 4 weeks if it is not tolerated.doseinsider.com

    Each step roughly doubles the one before: 0.25 to 0.5, 0.5 to 1, 1 to 1.7. The last regular step, from 1.7 to 2.4 mg, is the smallest in relative terms. The new step from 2.4 to 7.2 mg is the largest, a threefold jump, and the label restricts it accordingly.

    Is the maintenance dose 1.7 mg or 2.4 mg?

    Either. For weight reduction in adults the label says the maintenance dose "is either 1.7 mg or 2.4 mg (recommended)" and tells the prescriber to "consider treatment response and tolerability when selecting the maintenance dosage".1 The word "recommended" marks 2.4 mg as the default. It does not make 1.7 mg a failure.

    The evidence behind the two is uneven. Nearly all of the large trials aimed for 2.4 mg, and the headline results below are for that dose. The 1.7 mg dose was tested as a maintenance dose in one trial of 401 adults in Japan and South Korea, who were assigned to 2.4 mg, 1.7 mg or placebo.1 For teenagers the label gives the same pair of doses, and reports that in the trial of 12- to 17-year-olds, 5% of those who finished could not go beyond 1.7 mg.

    Who is the 7.2 mg dose for?

    Adults who are already settled on 2.4 mg and need to lose more. The label's wording is narrow: "For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly."1 It is not a starting dose and not a routine next step. It applies to weight reduction in adults only; for teenagers, for heart risk reduction and for liver disease the maximum stays at 2.4 mg.

    The dose was approved on the strength of two trials in which doses climbed over 20 weeks and were then held for a year. In the larger one, in adults with obesity and no diabetes, the average weight loss at week 72 was 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on placebo. The label gives the difference between the two doses as 3.3 points. In the second trial, in adults with type 2 diabetes, the figures were 13.2%, 10.4% and 3.8%.1

    The higher dose brought more side effects of one particular kind. Nausea was reported by 39 in 100 people on 7.2 mg, 35 on 2.4 mg and 13 on placebo, and vomiting by 22, 16 and 6. The clear difference was in altered skin sensations, such as tingling, burning or sensitivity to touch: 22 in 100 on 7.2 mg, 6 on 2.4 mg and none on placebo. Stopping because of side effects was no more common than on the lower dose, 5% in both groups against 2% on placebo.1

    So tripling the dose added about 3 points of weight loss on average and a new side effect for about one person in five. Whether that trade is worth it is a question the label leaves to "treatment response and tolerability".

    How does the Wegovy tablet schedule work?

    The tablet is taken every day and climbs in months. The starting dose is 1.5 mg once daily for 30 days, then 4 mg for 30 days, then 9 mg for 30 days, and from day 91 the maintenance dose of 25 mg.1 Switch the calculator to "Daily tablets" to see your dates.

    DaysTablet, once daily mgWhat it is
    1 to 301.5Starting dose
    31 to 604Step
    61 to 909Step
    91 onward25Maintenance dose

    The tablet has rules the injection does not. It is taken in the morning on an empty stomach, with no more than 4 ounces of plain water, swallowed whole. Food, drinks and other medicines taken by mouth wait at least 30 minutes. The label adds: "Do not take more than one tablet per day."1

    The numbers look very different from the injection, 25 mg a day against 2.4 mg a week, because only about 1 to 2% of a swallowed dose is absorbed, against 89% of an injected one. The label says the level of semaglutide in the blood on the 25 mg tablet is expected to be comparable to that on the 2.4 mg injection. In the tablet's main trial, 64 weeks long, the average weight loss was 13.6%.4

    If the 25 mg tablet is not tolerated, the label does not offer a lower tablet as a maintenance dose. It says to "consider switching to WEGOVY injection 1.7 mg once weekly".

    Switching between tablets and injections

    The label gives exact timing in both directions.1

    How does the drug build up through the steps?

    Slowly, by design. Semaglutide has a half-life of about a week, so each weekly dose arrives while more than half of the previous one is still there.1 The chart models the level through the injection schedule as a share of where it settles on your maintenance dose.

    Level in the body, step by stepModel from label half-life
    Maintenance dose
    Settled by—
    Starting level—

    A model, not a blood test: one compartment, half-life 7 days, peak at 48 hours; 100% is the settled weekly peak on the chosen dose. Dotted lines mark dose increases; the numbers along the bottom are weeks.

    The first month on 0.25 mg puts about a tenth of the 2.4 mg level in the body. This is why the first weeks tell you little about what the treatment will do, and why the label does not treat the early steps as doses to stay on. Our page on how long these drugs stay in the body has the same model for the weeks after a last dose.

    What did each dose deliver?

    Put your own weight in. The first view is the main trial of 2.4 mg, the second the trial that compared 7.2 mg with 2.4 mg, and the others show how many people reached a given loss on 2.4 mg.

    Results in your own weightFDA label, Tables 8 and 12
    Unit
    Show

    Weigh in once a week in the app and it plots your line against the trial average.

    Open the app

    All randomized participants. The two trials had different people and lengths, 68 and 72 weeks, so the 2.4 mg result differs between them: 14.9% in one, 15.5% in the other.

    In the main trial, 1,961 adults without diabetes took Wegovy 2.4 mg or placebo for 68 weeks, with the same 16-week climb as on the label.2 The average loss was 14.9% against 2.4%. A loss of at least 10% was reached by 66 in 100 people on Wegovy and 12 on placebo; at least 15% by 48 and 5; at least 20% by 30 and 2.1

    These are averages over everyone assigned to the drug, including people who stopped early. Like every result of this kind they describe a group. About one person in six on Wegovy did not reach a 5% loss, and nearly one in three lost more than a fifth of their body weight.

    How common are side effects on the way up?

    More common than on placebo for every stomach and bowel symptom, and most common for nausea. The label's table counts anyone who reported a symptom at any time during trials of up to 68 weeks.

    Out of 100 people on 2.4 mgFDA label, Table 3
    Side effect
    On Wegovy—
    On placebo—
    Would report it on placebo tooAdded by the drug

    Pooled trials in adults: 2,116 people on Wegovy 2.4 mg, 1,261 on placebo.

    Nausea was reported by 44 in 100 people on Wegovy and 16 on placebo, diarrhea by 30 and 16, vomiting by 24 and 6, constipation by 24 and 11.1 Few people gave up because of them: 6.8% stopped Wegovy for any side effect, against 3.2% on placebo, and nausea was the reason for 1.8%.

    The label gives one reason for the whole schedule, and it is these numbers: the climb exists "to reduce the risk of gastrointestinal adverse reactions". A dose reached in four gentle steps is tolerated by far more people than the same dose given at once would be.

    What if I cannot tolerate a step?

    The label has an answer for each stage of the schedule.1

    None of these is a failure of treatment. The label writes them into the schedule because the trials needed them too.

    Do other medicines matter during the climb?

    Two kinds, according to the label.1 Insulin and sulfonylureas can push blood sugar too low when taken with Wegovy, and the label says their dose may need to be lowered. If you take either, each step up is a moment to check with whoever prescribes them.

    For other medicines taken by mouth the label is cautious and brief. Wegovy slows the emptying of the stomach, which could change how a pill is absorbed. In studies with the 1 mg injection it did not, but with the tablet form the level of the thyroid medicine levothyroxine rose by 33%. The label asks for the effects of oral medicines to be monitored. Unlike the Zepbound label, it has no rule about backup contraception for people on birth-control pills.

    Is the schedule the same for teenagers?

    Yes, from age 12. The label uses one table for adults and for "pediatric patients aged 12 years and older": the same four steps of 4 weeks, then 2.4 mg, with 1.7 mg as the alternative.1 The 7.2 mg dose and the tablets are for adults only.

    The trial behind this enrolled 201 teenagers for 68 weeks, with a 16-week climb to 2.4 mg or the highest dose they tolerated. Of those who finished on Wegovy, 86.7% were on 2.4 mg at the end, and for 5% the highest tolerated dose was 1.7 mg. Stomach side effects were as common as in adults: nausea was reported by 42 in 100 on Wegovy and 18 on placebo, and vomiting by 36 and 10.

    What should I check before each step up?

    The label asks the prescriber to weigh two things, response and tolerability, and both are easier to discuss with notes than from memory. Three questions cover most visits.

    What if I miss a dose?

    For one missed injection, look at when the next one is due. If it is more than 2 days away, take the missed dose as soon as you can. If it is less than 2 days away, skip it and take the next dose on your regular day.1 In practice the missed dose can be taken up to 5 days late.

    Two missed doses in a row change the schedule itself. The current label says: "If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions." After a gap of two weeks or more you do not return to your old dose in one step. Your prescriber chooses a lower dose to restart from, and the calculator above can date the climb back.

    A missed tablet is simply skipped, and the next one is taken the following day. Our missed dose page checks the rule against your own dates.

    Which pens are there, and how are they stored?

    The injection now comes in three kinds of device, and the schedule is the same for all of them.1

    DeviceDoses insideStrengths
    Single-dose pen10.25, 0.5, 1, 1.7, 2.4 mg and 7.2 mg (Wegovy HD)
    Single-dose syringe10.25, 0.5, 1, 1.7, 2.4 mg
    FlexTouch pen42.4 mg per dose

    Single-dose pens and syringes are kept in the refrigerator at 36 to 46°F. If needed, before the cap is removed, they can be kept at 46 to 86°F for up to 28 days. They are kept in the carton, away from light, and thrown away after one use. The four-dose FlexTouch pen is refrigerated until first use, and the label gives it 56 days after that. The tablets are stored at room temperature in their original bottle, which protects them from moisture.

    Is the schedule different for other uses of Wegovy?

    The climb is identical "for all approved indications". The dose at the end differs.1

    Maintenance dose by use
    Weight reduction, adults1.7 or 2.4 mg; up to 7.2 mg
    Weight reduction, age 12 and older2.4 mg, or 1.7 mg
    Heart risk reduction2.4 mg, or 1.7 mg
    Liver disease (MASH)2.4 mg; 1.7 mg if needed
    Tablets25 mg daily

    How does it compare with the Zepbound schedule?

    Zepbound starts at 2.5 mg and rises by 2.5 mg, with at least 4 weeks on each dose, to a maintenance dose of 5, 10 or 15 mg.3 Its first maintenance dose arrives in week 5, where Wegovy's arrives in week 13. Zepbound's label sets only a minimum time on each step, so staying longer never needs a special provision. Wegovy's table fixes each step at 4 weeks and adds the 4-week delay as an option.

    The missed-dose windows differ by a day, 4 days for Zepbound and 5 for Wegovy, and only Wegovy's label spells out a restart at a lower dose after two missed weeks. Our Zepbound schedule page has the same calculator for that drug, and the head-to-head page covers the trial that compared the two.

    Short answers to common questions

    Can I stay on 1 mg if it is working?

    The label lists 1.7 and 2.4 mg as maintenance doses for weight reduction, and 0.25, 0.5 and 1 mg only as steps. Staying below 1.7 mg is outside the schedule as written and a decision for your prescriber.

    Can I skip a step to reach 2.4 mg faster?

    The label's table has no faster route. The steps exist to reduce stomach side effects, which are the main reason people stop.

    Is 7.2 mg three injections of 2.4 mg?

    The label lists a single-dose 7.2 mg pen, Wegovy HD. The dose is one injection once a week.

    Can I go back down from 7.2 mg?

    Yes. 1.7 and 2.4 mg remain maintenance doses, and the label tells the prescriber to choose the dose by response and tolerability.

    My pharmacy does not have the next strength. What now?

    Staying on the current strength for longer is the same as the delay the label describes for a dose that is not tolerated. Missing two or more doses in a row is different: the label then calls for starting the step-up again at a lower dose.

    What time of day should I inject?

    Any time, with or without a meal, on the same day each week. The label says the time of day and the injection site can be changed without changing the dose.

    How long do I stay on the maintenance dose?

    The label describes Wegovy as a treatment to reduce weight and keep it off long term and sets no end date. In the extension of the main trial, people who stopped regained about two-thirds of the weight they had lost within a year.5

    Do the tablets work as well as the injection?

    The label expects similar drug levels from the 25 mg tablet and the 2.4 mg injection. The tablet's main trial reported an average loss of 13.6% at 64 weeks; the injection's reported 14.9% at 68 weeks. They were separate trials.

    How the calculators on this page work

    The schedule calculator applies Table 1 of the label for the injection and Table 2 for the tablets. A delay adds 4 or 8 weeks to the last step before the maintenance dose. For 7.2 mg it adds the 4 weeks on 2.4 mg that the label requires first.

    The level chart is a one-compartment model with the label's half-life of about a week and a peak two days after each injection. It shows the shape of the build-up for the weekly injection and cannot show your own blood level. The results use the label's tables for all randomized participants, converted to your weight and rounded.

    Sources

    1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 3, 6.1, 12.3, 14.2 and 16, Tables 1, 2, 3, 4, 8 and 12. accessdata.fda.gov
    2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
    3. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 2. accessdata.fda.gov
    4. Overgaard RV, Agersø H, Hollensen C, Rathor N, Bomberg EM. The impact of missed doses on pharmacokinetic concentrations for oral semaglutide in comparison to other glucagon-like peptide-1-based therapies. Diabetes Obes Metab 2026;28:8735-8739; reports the 13.6% result of the tablet trial (OASIS 4). doi:10.1111/dom.71030
    5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564. doi:10.1111/dom.14725

    Related analyses

    Log each dose and see your next step by date.

    Open Dose Insider